The 4 Cardiology High-Yield Concepts Every FNP Student Must Master Before Boards

Cardiology · 4 min read · November 4, 2026

Demystifying Cardiac Auscultation and Murmurs

Cardiology questions are a guaranteed staple on both the AANP and ANCC family nurse practitioner certification exams. When it comes to heart murmurs, students often panic, but the secret to mastering them lies in understanding radiation, timing, and dynamic maneuvers. A systolic murmur occurs between S1 and S2, while a diastolic murmur occurs between S2 and S1—and remember, all diastolic murmurs are pathological and require immediate cardiology referral.

To ace these questions on exam day, focus on classic radiation patterns. Mitral regurgitation typically radiates to the left axilla, whereas aortic stenosis radiates distinctively to the neck and carotids. Listen closely to how maneuvers change the sound: Valsalva strain and standing decrease venous return, which decreases the intensity of most murmurs, except for hypertrophic cardiomyopathy (HCM) and mitral valve prolapse (MVP), which both get louder or occur earlier.

Board Clinical Pearl: In hypertrophic cardiomyopathy, maneuvers that decrease preload—like standing or straining down during a Valsalva maneuver—make the murmur louder because the ventricular chambers narrow, accentuating the outflow obstruction.

Navigating Heart Failure Stages and Pharmacotherapy

Heart failure management is another heavy hitter on board exams, particularly regarding guideline-directed medical therapy (GDMT). You need to clearly differentiate between heart failure with reduced ejection fraction (HFrEF, EF $\le$ 40%) and heart failure with preserved ejection fraction (HFpEF, EF $\ge$ 50%). For HFrEF, the foundational four-pillar drug class regimen includes an ARNI (or ACE inhibitor/ARB), a beta-blocker (specifically carvedilol, metoprolol succinate, or bisoprolol), an aldosterone receptor antagonist (spironolactone), and an SGLT2 inhibitor.

Board questions love to test your knowledge of drug contraindications and monitoring parameters. For example, before starting an ACE inhibitor or ARNI, you must check baseline serum creatinine and potassium levels, as well as monitor for hyperkalemia and renal function decline. Furthermore, ACE inhibitors are famous for causing a dry, persistent cough due to bradykinin accumulation; if a patient develops this, smoothly transition them to an ARB.

Board Clinical Pearl: ARNIs like sacubitril/valsartan require a mandatory 36-hour washout period when switching from an ACE inhibitor to prevent severe, life-threatening angioedema.

Interpreting Lipid Panels and ASCVD Risk Calculation

Dyslipidemia management under the latest ACC/AHA guidelines heavily emphasizes risk stratification rather than strict target cholesterol numbers alone. When evaluating a patient, you must calculate their 10-year atherosclerotic cardiovascular disease (ASCVD) risk score. If a patient has clinical ASCVD, they automatically fall into the high-risk category and require high-intensity statin therapy (such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg), which aims to lower LDL-C by at least 50%.

For primary prevention patients aged 40 to 75 with diabetes or an LDL-C level of 190 mg/dL or higher, statin initiation is straightforward. However, for borderline or intermediate risk patients (10-year risk of 7.5% to <20%), use risk-enhancing factors—such as a family history of premature CAD, chronic kidney disease, or metabolic syndrome—to guide shared decision-making regarding moderate-intensity statin therapy.

Board Clinical Pearl: High-intensity statins cut LDL-C by $\ge$ 50%, moderate-intensity statins cut it by 30% to <50%, and low-intensity statins cut it by <30%. Memorize this breakdown because board exams frequently test appropriate statin dosing categories.

Hypertension Guidelines and Target Blood Pressures

Hypertension management is woven into almost every clinical case vignette on the FNP boards. Remember the current classification standards: normal blood pressure is less than 120/80 mmHg, elevated is 120–129/<80, Stage 1 is 130–139/80–89, and Stage 2 is $\ge$ 140/$\ge$ 90 mmHg. For most adults, the treatment threshold and target goal is less than 130/80 mmHg if they have clinical CVD or a 10-year ASCVD risk of 10% or higher.

First-line antihypertensive classes for non-black patients include thiazide diuretics, CCBs, and ACE inhibitors or ARBs. For black patients without chronic kidney disease, initial therapy should focus on thiazide diuretics or calcium channel blockers, as they respond exceptionally well to these classes compared to ACE inhibitors alone. Always screen for secondary causes of hypertension—such as renal artery stenosis or primary aldosteronism—in patients with resistant hypertension who fail three optimized medications including a diuretic.

You have everything it takes to master cardiology and pass your boards with flying colors. Keep showing up for yourself every single day, trust your clinical instincts, and let's get you across that finish line.